Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 39
Filtrar
1.
J Physiol Pharmacol ; 70(3)2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31566192

RESUMEN

Heparanase concentration is low in normal epithelia cells but its overexpression is reported in many carcinomas, including sarcomas and haematological malignancies. The purpose of this study was to investigate the association with selected angiogenic parameters as well as in the number of circulating endothelial progenitors (EPCs) in respect to low, moderate and high concentrations of heparanase. Also, we estimated the diagnostic usefulness of the heparanase concentration for disease recurrence prediction in breast cancer cases. Eighty-six patients with IA-IIB stage invasive breast carcinoma who passed a comprehensive clinicopathologic evaluation were included in the study. The median tumour diameter was 1.5 cm. Twenty cases showed lymph node metastasis (N1). Follow-up was completed in all patients a median follow-up was 33.5 months with a 11.6% recurrence rate. An immunoassay of selected angiogenic parameters, heparanase, as well as an immunohistochemistry of oestrogen and progesterone receptors, human epidermal growth factor receptor 2 (HER2), Ki67 and E-cadherin was performed in all cases. Circulating EPCs were determined by flow cytometry. Higher levels of heparanase in oestrogen and progesterone receptor negative cancers than in positive ones were noted. A higher concentration of heparanase was observed in T2 cases than T1 subjects. Significant positive associations between circulating EPCs, soluble forms of VEGF receptors and increasing plasma levels of heparanase were obtained. Follow-up revealed a significantly higher incidence of disease relapse in breast cancer patients with high baseline concentrations of heparanase. Heparanase was the most accurate biomarker with an AUCROC = 0.72. The cut-off value of 213.74 pg/mL was identified in order to discriminate between disease recurrence patients and those without disease relapse. We suggest, that a high concentration of heparanase next to tumour size and oestrogen and progesterone receptor expression may serve as an indicator of a more an aggressive character of tumour cells and a shorter survival rate.


Asunto(s)
Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Glucuronidasa/metabolismo , Neovascularización Patológica/metabolismo , Neovascularización Patológica/patología , Adulto , Anciano , Neoplasias de la Mama/mortalidad , Femenino , Humanos , Inmunohistoquímica/métodos , Metástasis Linfática/patología , Masculino , Persona de Mediana Edad , Receptor ErbB-2/metabolismo , Receptores de Progesterona/metabolismo , Tasa de Supervivencia
2.
J Physiol Pharmacol ; 69(6)2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30802214

RESUMEN

The aim of this study was to evaluate the concentrations of tissue factor (TF) and its inhibitor (TFPI), vascular endothelial growth factor A (VEGF-A), soluble forms of VEGF receptors type 1 and 2 (sVEGFR1 and aVEGFR2) in patients diagnosed with luminal A breast cancer (BrC) and in healthy individuals and to find associations of analyzed factors with demographic, clinical and pathological characteristics in a homogeneous breast cancer group. Study group consisted of 60 women aged 40 - 69 years, diagnosed with luminal-A subtype of BrC, without distant metastases (M0). Control group comprised 40 healthy women aged 45 - 63 years. Blood samples were collected from each patient in order to determine plasma levels of TF, TFPI, VEGF-A and sVEGFR1 and sVEGFR2. The examined parameters were measured by enzyme-linked immunosorbent assay (ELISA). The capacity of angiogenic and hemostatic parameters in predicting neoplasm disease was analyzed using receiver operating characteristic (ROC) curve analysis. According to ROC curve analysis, the optimum cut-off point for TF was 304.58 pg/ml, with 100% sensitivity and 100% specificity, which was calculated to discriminate between controls and malignancy patients. In luminal A BrC patients there were significantly higher concentrations of VEGF-A and TF than in controls. On the contrast the levels of sVEGF receptors type 1 and 2 as well as TFPI in luminal-A BrC cases were significantly lower in respect to healthy volunteers. Levels of examined factors in the study group varied depending on age, menopausal status, lymph node involvement and histological type. We concluded that altered levels of examined factors in patients diagnosed with luminal-A breast cancer indicate increased activation of angiogenesis and hemostasis. The results obtained may be indicative of a mutual connection between angiogenesis and hemostasis processes in tumor development and progression. Clinical and pathological parameters may possibly affect levels of angiogenic and coagulation factors.


Asunto(s)
Biomarcadores de Tumor/sangre , Neoplasias de la Mama/diagnóstico , Neovascularización Patológica/patología , Tromboplastina/metabolismo , Adulto , Anciano , Neoplasias de la Mama/sangre , Estudios de Casos y Controles , Ensayo de Inmunoadsorción Enzimática , Femenino , Hemostasis , Humanos , Lipoproteínas/sangre , Persona de Mediana Edad , Factor A de Crecimiento Endotelial Vascular/sangre , Receptor 1 de Factores de Crecimiento Endotelial Vascular/sangre , Receptor 2 de Factores de Crecimiento Endotelial Vascular/sangre
3.
Transplant Proc ; 39(9): 2744-7, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18021975

RESUMEN

BACKGROUND: One of the most often occurring complications after a kidney transplantation is a lymphocele. MATERIALS: The examined group consisted of 118 patients (70 males and 48 females) with end-stage renal disease (ESRD). RESULTS: Fourteen patients (12%) developed symptoms of lymphocele within an average time of 34 weeks. The clinical symptoms included the following: decreased 24-hour urine collection and increased creatinine level, abdominal discomfort, lymphorrhoea with surgical wound dehiscence, urgency, vesical tenesmus, and/or fever. Increased appearance of lymphocele was noticed in patients with diabetic nephropathy, congenital malformations of the urinary tract, and inflammatory diseases, including glomerulopathy and extraglomerular ones, after high-voltage radiotherapy and after removal of the renal graft. The methods of treatment and their efficacy were as follows: percutaneous aspiration with the ratio of recurrence 100%; ultrasound guided percutaneous drainage 50%; laparoscopic intraabdominal marsupialization 75%; and surgical intervention with favorable results. CONCLUSIONS: Ultrasound-guided percutaneous drainage with a success rate greater than 50% should be recommended as the first line of treatment. As a minimal invasive surgery this kind of treatment does not interfere with subsequent internal drainage through an open or a laparoscopic surgery. Laparoscopy, a feasible, safe technique with a success rate of more than 80%, should be used routinely after unsuccessful percutaneous drainage.


Asunto(s)
Trasplante de Riñón/efectos adversos , Linfocele/epidemiología , Nefropatías Diabéticas/complicaciones , Nefropatías Diabéticas/cirugía , Drenaje , Femenino , Estudios de Seguimiento , Humanos , Fallo Renal Crónico/etiología , Fallo Renal Crónico/cirugía , Laparoscopía , Linfocele/diagnóstico , Linfocele/fisiopatología , Linfocele/terapia , Masculino , Dolor , Estudios Retrospectivos , Factores de Tiempo
4.
J Physiol Pharmacol ; 68(1): 139-148, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28456778

RESUMEN

The aim of the study was to evaluate the number of circulating endothelial progenitor cells (circulating EPCs) in the blood of patients diagnosed with breast cancer and to make an attempt at finding associations with the number of circulating EPCs and selected clinic-pathological factors; TNM and histological grading, molecular subtype of breast cancer, hormonal status, the expression of Ki-67 and the size of tumour. The study involved 96 Caucasian ethnicity post-menopausal women. Sixty-six women aged 48 - 63 (mean age 55) with breast cancer diagnosis without distant metastases (M0). The median value of the tumour diameter was 1.51 cm. The control group consisted of 30 healthy, non-smoking, post-menopausal women, mean age 49, range 44 - 54 years of age. The exclusion criteria for all the participants were hypertension, hyperlipidaemia, and hyperglycaemia, acute and chronic infection. With regard to the fresh blood samples the number of circulating endothelial progenitors was determined using flow cytometry. The fluorescence of 100,000 cells was measured during the analysis. Circulating EPCs were identified with the immune-phenotype CD45-, CD34+, CD133+, CD31+. A significantly higher number of circulating EPCs in the study group, as compared to the controls (P = 0.0001) and a significantly higher number of circulating EPCs in women over 60 with breast cancer than in the younger women (P = 0.0029) were reported. A positive correlation was noted between circulating EPCs and age as well as between circulating EPCs and HER-2 (P = 0.0231, P = 0.0414, respectively), and a negative correlation between circulating EPCs and histological grading of breast cancer (P = 0.0272). The study has shown a higher number of circulating EPCs in breast cancer patients, which indicates stimulation of neovascularization. Additionally, since bone morrow-derived circulating EPCs are more intensively mobilised in older and overweight breast cancer patients, we can speculate that more aggressive neo-angiogenesis can occur in those patients.


Asunto(s)
Neoplasias de la Mama/patología , Células Progenitoras Endoteliales/patología , Adulto , Antígenos CD/inmunología , Neoplasias de la Mama/inmunología , Neoplasias de la Mama/metabolismo , Femenino , Humanos , Antígeno Ki-67/metabolismo , Persona de Mediana Edad , Neovascularización Patológica , Posmenopausia , Carga Tumoral
5.
J Physiol Pharmacol ; 67(4): 555-561, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27779476

RESUMEN

Adipokines regulate glucose homeostasis, insulin sensitivity, lipids metabolism, reproduction, as well as endothelial and platelets function. The study compares the plasma and adipose tissue concentrations of total adiponectin, leptin, leptin receptor and leptin-to-adiponectin ratio (LAR) in morbidly obese patients. Additionally it evaluates selected adipokines (leptin, adiponectin), endothelial markers and LAR depending on the gender in morbidly obese and non-obese subjects. The study involved 51 patients (31 women aged 21 - 60 (mean age of 39) and 20 men aged 24 to 60 (mean age of 41)). The eligibility criterion included the BMI ≥ 40 kg/m2. The non-obese group consisted of 30 healthy volunteers with the BMI < 24.9 kg/m2; nineteen women, aged 24 - 53 (mean age of 41), and 11 men aged 21 - 52 (mean age of 38). In the plasma and adipose tissue, the concentrations of total adiponectin, leptin, leptin receptor and plasma soluble forms of E-selectin, P-selectin, thrombomodulin were measured applying immunoassay techniques. There were noted significantly higher plasma leptin and sE-selectin concentrations, leptin-to-adiponectin ratio, additionally lower concentrations of plasma leptin receptor and sP-selectin in obese subjects regardless of the gender. Significantly higher concentrations of total adiponectin, leptin, leptin receptor expressed per 1 mg of total protein in adipose tissue, as compared to plasma in morbidly obese patients, were observed. Significant positive correlations between the BMI and the concentration of leptin and between total adiponectin and sP-selectin were reported in the subject group. Similarly there were noted significant negative correlations between leptin receptor and the BMI and between leptin-to-adiponectin ratio and sP-selectin in obese patients. The study has shown that adiponectin has a positive impact on platelets through a possible reduction in sP-selectin, and thus on platelets activation. On the other hand an elevated sE-selectin reveals perspective about the endothelium stimulation and a higher risk of endothelial damage in morbidly obese patients. Also in morbidly obese the higher leptin level and leptin-to-adiponectin ratio and simultaneously lower concentration of leptin receptor are associated with leptin resistance, additionally in possible future risk of insulin resistance and diabetes type 2.


Asunto(s)
Adiponectina/metabolismo , Plaquetas/fisiología , Leptina/metabolismo , Obesidad Mórbida/metabolismo , Adiponectina/sangre , Tejido Adiposo/metabolismo , Adulto , Selectina E/sangre , Femenino , Humanos , Leptina/sangre , Masculino , Persona de Mediana Edad , Obesidad Mórbida/sangre , Selectina-P/sangre , Pruebas de Función Plaquetaria , Receptores de Leptina/sangre , Receptores de Leptina/metabolismo , Trombomodulina/sangre , Adulto Joven
6.
Int Angiol ; 34(6): 545-51, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25394959

RESUMEN

AIM: The number of people suffering from atherosclerosis-related complications such as peripheral arterial disease (PAD) ­ including lower limbs PAD increases. Hypoxia and ischemia stimulate angiogenesis ­ a postnatal multistage process in which new blood vessels form and the Vascular Endothelial Growth Factor (VEGF-A) is the key proangiogenic factor whereas its soluble receptors type 1 and type 2 (sVEGFR-1, sVEGFR-2) are regarded as inhibitory factors. The aim of this study was to assess the concentrations of VEGF-A, sVEGFR-1 and sVEGFR-2 in plasma of patients with symptomatic lower extremity PAD compared with selected clinical parameters (Ankle-Brachial Index, distance in walking test) and severity of PAD (according to the Fontaine classification). METHODS: The study group included 46 patients suffering from symptomatic PAD with Fontaine class IIa-IV without any history of neoplastic disease. The control group consisted of 30 healthy non-smoking volunteers. The following parameters were determined: plasma concentrations of VEGF-A, its soluble receptors (sVEGFR-1, sVEGFR-2) using the ELISA method also VEGF-A and sVEGFR-1 quotient was calculated on the basis of mean concentrations in homogenous units (pg/mL). RESULTS: The study group revealed a statistically significant higher level of VEGF-A concentration when compared with the control group and statistically significant lower concentration of sVEGFR-2 in the study group. In the study group a statistically significant negative correlation between VEGF-A concentrations and the length of irrelative distance in walking test was observed. In the group of PAD a significantly higher VEGF-A/sVEGFR-1 ratio in comparison with the control group was obtained. Within the group of patient suffering from PAD there was noticed an increasing VEGF-A/sVEGFR-1 ratio in subsequent subgroups according to the Fontaine classification. CONCLUSION: The plasma concentrations of VEGF-A correlated with increased clinical symptoms of PAD in the walking test. The plasma VEGF-A/sVEGFR-1 ratio may be used as a useful ischemic marker in patients with PAD which should be tested and finally verified in large group of patients.


Asunto(s)
Isquemia/sangre , Neovascularización Patológica/sangre , Enfermedad Arterial Periférica/diagnóstico , Factor A de Crecimiento Endotelial Vascular/sangre , Receptor 1 de Factores de Crecimiento Endotelial Vascular/sangre , Receptor 2 de Factores de Crecimiento Endotelial Vascular/sangre , Anciano , Índice Tobillo Braquial , Biomarcadores/sangre , Femenino , Humanos , Extremidad Inferior/irrigación sanguínea , Extremidad Inferior/fisiopatología , Masculino , Persona de Mediana Edad , Enfermedad Arterial Periférica/sangre , Índice de Severidad de la Enfermedad
7.
Thromb Haemost ; 60(3): 372-6, 1988 Dec 22.
Artículo en Inglés | MEDLINE | ID: mdl-3149044

RESUMEN

A decrease in the fibrinolytic potential, mainly due to an elevation of plasminogen activator inhibitor (PAI), has been described in patients with stable coronary artery disease and a previous myocardial infarction. We investigated plasma levels of PAI and tissue plasminogen activator (t-PA) and their possible circadian variations in patients with unstable coronary artery disease (CAD). Sixty-three patients were studied for at least 2 consecutive days during their stay at the coronary care unit (CCU). Diurnal plasma fluctuations in PAI and t-PA and onset of further myocardial ischemic episodes were monitored. As controls we used 22 age-matched patients submitted to the clinic because of non cardiac chest pain or valvular disease who revealed no evidence of CAD. PAI levels were significantly elevated in patients with unstable CAD (p less than 0.0001) but were not influenced by the extent of underlying CAD, history of previous myocardial infarction, known risk factors for CAD, or by extent of myocardial damage. The circadian variation of PAI levels with peak values between midnight and 6 A.M. found in controls was still present in patients but at a higher level. Preservation of circadian pattern in PAI plasma levels despite myocardial ischemic attacks indicates that elevation of PAI is rather not caused by a reactive phenomenon. On the other hand, elevated PAI levels and episodes of severe myocardial ischemia exhibiting a median time of onset at 10 A.M. seem to be closely related.


Asunto(s)
Ritmo Circadiano , Enfermedad Coronaria/sangre , Glicoproteínas/sangre , Infarto del Miocardio/sangre , Activadores Plasminogénicos/antagonistas & inhibidores , Inactivadores Plasminogénicos , Activador de Tejido Plasminógeno/sangre , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo
8.
Thromb Res ; 55(6): 779-84, 1989 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-2506671

RESUMEN

Patients with unstable coronary artery disease were randomly treated either with a combination therapy consisting of nitrates and calcium-channel blockers without or with addition of clinical grade heparin administered subcutaneously; in order to evaluate the effect of heparin treatment on the fibrinolytic system, tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) plasma levels were related to the clinical course of the disease. In heparinized patients thrombin time was prolonged more than 3-fold the normal range indicating effective heparin treatment. Heparinization led to a significant increase in t-PA antigen plasma levels (p less than 0.0001) within approximately four hours while PAI-1 activities remained unaltered. However, the measurable increase of the anticoagulant and pro-fibrinolytic activities of heparin did not result in a short-term benefit for the heparinized patients because the number of further ischemic attacks per patient during the observation period of three days was not different between the two study groups.


Asunto(s)
Angina de Pecho/tratamiento farmacológico , Angina Inestable/tratamiento farmacológico , Heparina/uso terapéutico , Activador de Tejido Plasminógeno/sangre , Anciano , Angina Inestable/sangre , Femenino , Glicoproteínas/sangre , Humanos , Masculino , Persona de Mediana Edad , Inactivadores Plasminogénicos , Distribución Aleatoria , Activador de Tejido Plasminógeno/antagonistas & inhibidores
9.
Blood Coagul Fibrinolysis ; 8(1): 1-5, 1997 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9105630

RESUMEN

In order to investigate changes in coagulation and fibrinolysis arising during and after laparoscopic surgery we studied 24 patients, who were operated on because of biliary lithiasis [21 females, three males, aged 36-69 (mean 50) years]. The reference group consisted of 17 patients, who were operated on traditionally [15 females, two males, aged 25-72 (mean 55) years]. Blood samples were taken from cubital vein 24 h prior to the operation, during the cholecystectomy, on the 1st and 3rd postoperative days. Additionally, before and during operation blood was sampled simultaneously from femoral vein. Both groups had similar perioperative values of platelet count, fibrinogen and t-PA Ag. Patients operated on laparoscopically had generally lower values of F1 + 2 and plasmin-alpha 2-antiplasmin complexes, and intra-operative PAI-1 activity than those operated on traditionally. Test values in blood sampled simultaneously from femoral and cubital veins were not statistically different. The data obtained show that generation of thrombin and plasmin is lower in patients operated on laparoscopically compared with those having traditional surgery. Venous stasis during laparoscopic cholecystectomy in lower extremities does not cause local alterations in hemostasis.


Asunto(s)
Colecistectomía/efectos adversos , Fibrinólisis , Laparoscopía/efectos adversos , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recuento de Plaquetas
10.
Neurol Neurochir Pol ; 35 Suppl 5: 130-4, 2001.
Artículo en Polaco | MEDLINE | ID: mdl-11935674

RESUMEN

UNLABELLED: Von Willebrand factor (vWF) plays an important role in the coagulation system. It affects platelet aggregation in the place of vessel endothelium damage. The importance of vWF in cerebrovascular disease is not clear. The aim of this presentation was to evaluate the vWF level in the plasma and cerebrospinal fluid of patients after subarachnoid hemorrhage including cases with cerebral vasospasm and cerebral infarct. We investigated 66 patients (38 persons graded I-III H&H and 28 persons graded IV H&H). The control group consists of 8 subjects. VWF was measured by ELISA method using standard kit Asserachrom (Boehringer). The vWF level in the plasma reached 288.81 +/- 99.66% (in the control group, 98.84 +/- 14.53%) without significant differences regarding clinical condition of patients. In the cerebrospinal fluid the vWF level was significantly different in I-III H&H patients and in IV H&H patients (1.21 +/- 0.52% and 9.18 +/- 7.58%, respectively, p < 0.001) and in the control group (0.13 +/- 0.33%). Our data indicate that there is correlation (Pearson, p < 0.01) between the level of vWF and neurological condition (GCS) of patients. There is also correlation (p < 0.01) between the level of VWF and the presence of clinical disorders (cerebral vasospasm, delayed neurological deficit (DIND) and cerebral infarct). Based on multivariate analysis, we confirmed that vWF is an independent prognostic factor of cerebral vasospasm (p < 0.01) and ischemic complications (p < 0.02). CONCLUSIONS: vWF is elevated in the plasma of patients after subarachnoid hemorrhage in early stage of the disease. VWF is present in the cerebrospinal fluid of patients with SAH and its level is higher in patients with poor neurological condition. The VWF elevation in csf is correlated with clinical condition of patients and also the presence of cerebral vasospasm and cerebral infarct. VWF can be used as an independent prognostic factor of cerebral vasospasm and ischemic complications.


Asunto(s)
Hemorragia Subaracnoidea/sangre , Hemorragia Subaracnoidea/líquido cefalorraquídeo , Factor de von Willebrand/metabolismo , Adulto , Estudios de Casos y Controles , Infarto Cerebral/sangre , Infarto Cerebral/líquido cefalorraquídeo , Infarto Cerebral/etiología , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Hemorragia Subaracnoidea/complicaciones , Hemorragia Subaracnoidea/cirugía , Vasoespasmo Intracraneal/sangre , Vasoespasmo Intracraneal/líquido cefalorraquídeo , Vasoespasmo Intracraneal/etiología , Factor de von Willebrand/líquido cefalorraquídeo
11.
Neurol Neurochir Pol ; 30(3): 427-34, 1996.
Artículo en Polaco | MEDLINE | ID: mdl-8965977

RESUMEN

The following factors of fibrinolysis: tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor-1 (PAI-1) play an important role in patients after trauma. Their possible mechanisms in head-injured patients remain unknown. We studied the maintenance of those markers of fibrinolysis in the plasma and cerebrospinal fluid of 19 patients after severe head injury (initially GCS less than 8 p) without intracranial haematoma. We measured changes of the level of t-PA antigen and PAI-1 activity in days 0-3, 4-6 and later. T-PA antigen level in the plasma was higher than normally (4-8 ng/ml). T-Pa was present in the cerebrospinal fluid, but its level reached only 30% of the plasma level. In the days following injury the t-PA antigen level decreased. The PAI-1 activity in the plasma was normal (0-15 IU/ml). However, its activity in csf was high and reached, 80% of the plasma level and systematically increase in the following days particularly in patients who died. PAI-1 activity can be connected with the presence of damaged brain tissue and its necrosis and its increase can be a marker of poor prognosis.


Asunto(s)
Lesiones Encefálicas/fisiopatología , Inactivadores Plasminogénicos/sangre , Activador de Tejido Plasminógeno/sangre , Adulto , Femenino , Fibrinólisis , Humanos , Masculino , Inactivadores Plasminogénicos/líquido cefalorraquídeo , Pronóstico , Activador de Tejido Plasminógeno/líquido cefalorraquídeo
12.
Pol Merkur Lekarski ; 7(43): 9-11, 2000 Jan.
Artículo en Polaco | MEDLINE | ID: mdl-10765644

RESUMEN

Forty one patients with recently recognised bronchial asthma were studied. Activity of plasminogen activator inhibitor (PAI-1), platelet adhesion and aggregation, antigens of tissue and urokinase plasminogen activators (respectively, t-PA Ag and u-PA Ag), euglobulin lysis time (ELT), complexes of plasmin-antiplasmin (PAP) and fibrin degradation products (FDP) were tested before and after fourteen days administration of 20-30 mg/d prednisone. Statistical significant increase of PAI-1 activity, on the average about 75%, was found (8.35 +/- 9.38 U/ml before, and 14.6 +/- 13.3 U/ml after treatment; p < 0.02). In 31 asthmatic patients (75.6%), after prednisone treatment, increased of PAI-1 activity together with platelet adhesion and aggregation were observed. Among other studied fibrinolysis factors no statistical significant differences before and after treatment were found. These results suggest that in asthmatic patients after prednisone treatment raises PAI-1 activity, probability because of releasing of the increased amount of PAI-1 from activated platelet.


Asunto(s)
Antiinflamatorios/farmacología , Asma/tratamiento farmacológico , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , Fibrinólisis/efectos de los fármacos , Prednisona/farmacología , Adulto , Anciano , Antiinflamatorios/uso terapéutico , Asma/sangre , Femenino , Fibrinolisina/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Inhibidor 1 de Activador Plasminogénico/metabolismo , Prednisona/uso terapéutico , Valores de Referencia , Seroglobulinas/metabolismo , Factores de Tiempo , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo
13.
Pol Merkur Lekarski ; 11(61): 40-3, 2001 Jul.
Artículo en Polaco | MEDLINE | ID: mdl-11579829

RESUMEN

The aim of the work was to evaluate the von Willebrand factor antigen (vWF Ag) concentration in the blood plasma of hemodialysed patients with chronic renal failure. The study was performed in the group of 43 patients (means aged 42.8 years) with chronic renal failure dialysed means 4 hours 3 times a week. The blood was obtained before and after hemodialyze and in 11 patients additionally after 1 year of systematic hemodialyze. The control group consisted of 51 healthy volunteers means aged 35.6 years. In the citric blood plasma concentration of vWF Ag was determined using immunosorbed enzyme-linked assay (ELISA). In the blood plasma of patients with chronic renal failure significantly higher concentration of vWF Ag than in controls was observed. 4-hours and 1-year dialyze did not influence the level of vWF Ag in patients with chronic renal failure.


Asunto(s)
Antígenos/sangre , Fallo Renal Crónico/sangre , Fallo Renal Crónico/terapia , Adulto , Anciano , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Masculino , Persona de Mediana Edad , Diálisis Renal , Factor de von Willebrand/inmunología
14.
Pol Merkur Lekarski ; 2(7): 24-5, 1997 Jan.
Artículo en Polaco | MEDLINE | ID: mdl-9296893

RESUMEN

The aim of study was the evaluation of tissue plasminogen activator (t-PA) and its inhibitor (PAI-1) in the II type diabetes on the base of the common fibrinolytic system tests as euglobulin lysis time (ELT) and the concentration of fibrin/fibrinogen products (FDP). The studies were performed in 21 outpatients suffering of II type diabetes aged 38-65 (median 56.0) years treated with diet and sulphonylcarbamide derivates. The control group contained 18 healthy persons aged 33-65 (median 42.0) years. In the blood the following determinations were performed: antigen of t-PA and PAI-1, ELT and FDP. In the blood of patients with II type diabetes increased. t-PA Ag and PAI-1 Ag concentrations were observed.


Asunto(s)
Diabetes Mellitus Tipo 2/fisiopatología , Inactivadores Plasminogénicos/fisiología , Activador de Tejido Plasminógeno/fisiología , Adulto , Anciano , Fibrinólisis/fisiología , Humanos , Persona de Mediana Edad
15.
Pol Merkur Lekarski ; 6(32): 79-81, 1999 Feb.
Artículo en Polaco | MEDLINE | ID: mdl-10337177

RESUMEN

The aim of the study was to evaluate function of endothelial cells in the patients with hyperthyrosis before thyrostatic treatment on the base of known markers of endothelial disturbances: von Willebrand factor and tissue plasminogen activator. The study was performed in the 36 patients aged 20-60 (means 36.7) years suffering from Graves disease and in 17 patients with hyperthyrotic goitre aged 30-59 (means 45.8). The control group consisted of 40 healthy volunteers. In the blood plasma concentration of tissue plasminogen activator (t-PA) and von Willebrand factor (vWF) antigen were determined with enzyme-linked immunoassay (ELISA). In patients with hyperthyroidism significantly increased antigen concentration of both studied parameters were observed. It seems that increased concentration of t-PA and vWF antigen in the blood of hyperthyrotic patients was the result of the release of them from injured thyroid gland by disease or of stimulating effect of thyroid hormones on the t-PA and vWF synthesis in the endothelial cells.


Asunto(s)
Endotelio/citología , Endotelio/fisiología , Hipertiroidismo/sangre , Activador de Tejido Plasminógeno/fisiología , Factor de von Willebrand/fisiología , Adulto , Biomarcadores , Femenino , Humanos , Masculino , Persona de Mediana Edad
16.
Pol Merkur Lekarski ; 11(65): 414-7, 2001 Nov.
Artículo en Polaco | MEDLINE | ID: mdl-11852811

RESUMEN

UNLABELLED: The aim of the study was to evaluate plasminogen activators in compare fibrinolysis parameters in patients with atherosclerosis obliterans (AO) and diabetic macroangiopathy (DM) of lover extremities. The study group consist of 40 patients with AO (mean age 59 years) and 40 with DM (mean age 61 years). All the patients were diagnosed as the II stage in Fontaine scale. Ischemia lover extremities were: aorta-hip, femoral-popliteal and peripheral dependent closure. The control group consist of 30 healthy volunteers (mean age 51 years). Concentration of: tissue plasminogen activator antigen (t-PA:Ag), urokinase plasminogen activator antigen (u-PA:Ag), plasminogen activator inhibitor type 1 antigen (PAI-1:Ag) (ELISA), PAI-1 activity (PAI-1 act.), euglobulin lysis time (ELT) (Kowarzyk-Buluk method), fibrinogen, fibrin degradation products (FDP) (Merskey method) in blood plasma were evaluated. The results shows statistically higher concentrations of: t-PA:Ag, PAI-1:Ag, fibrinogen, and lower concentrations of u-PA:Ag and elongated ELT in blood plasma patients with AO and DM in compare with healthy volunteers. Comparing analysed parameters between patient groups shows higher concentration FDP in patients with AO than patients with DM. CONCLUSIONS: 1) Although elongated ELT in both groups it was shown evidence of the fibrinolysis activation in the shape of elevated FDP concentration. It was probably compensation for hypercoagulability. 2) Elevated t-PA:Ag concentration in patients with AO and DM is an evidence of the higher releasing of the endothelium in AO and DM.


Asunto(s)
Arteriosclerosis Obliterante/sangre , Angiopatías Diabéticas/sangre , Fibrinólisis , Activador de Tejido Plasminógeno/sangre , Activador de Plasminógeno de Tipo Uroquinasa/sangre , Adulto , Anciano , Antitrombinas/metabolismo , Estudios de Casos y Controles , Ensayo de Inmunoadsorción Enzimática , Femenino , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , Fibrinógeno/metabolismo , Humanos , Pierna , Masculino , Persona de Mediana Edad , Inhibidor 1 de Activador Plasminogénico/sangre , Inhibidores de Serina Proteinasa/sangre , Seroglobulinas/metabolismo
17.
Pol Merkur Lekarski ; 1(4): 235-7, 1996 Oct.
Artículo en Polaco | MEDLINE | ID: mdl-9156932

RESUMEN

The aim of work was to study whether activity and antigen level of tissue plasminogen activator (t-PA) and activity of plasminogen activator inhibitor (PAI-1) were related to severity and extensiveness of vascular lesions in peripheral obliterative atherosclerotic disease (POAD). The study group consisted of 25 patients in II (13), III (10) and IV (2) degrees of disease acc. to Fontaine'a. In the blood t-PA activity and antigen and activity of PAI-1 were determined. In the patients with more severe POAD higher t-PA antigen and increased t-PA complexed with PAI-1 were observed. In patients with unisegmental POAD twice t-PA activity than in patients with polysegmental atherosclerotic lesions was detected.


Asunto(s)
Arteriosclerosis/fisiopatología , Pierna/irrigación sanguínea , Enfermedades Vasculares Periféricas/fisiopatología , Inhibidor 1 de Activador Plasminogénico/sangre , Activador de Tejido Plasminógeno/inmunología , Anciano , Antígenos/análisis , Humanos , Persona de Mediana Edad
18.
Pol Merkur Lekarski ; 6(33): 135-7, 1999 Mar.
Artículo en Polaco | MEDLINE | ID: mdl-10365597

RESUMEN

The aim of study was to evaluate the influence of the treatment with oxygen-ozone mixture on the blood plasma antigen concentration of tissue plasminogen activator (t-PA) and von Willebrand factor (vWF) in patients suffering from atherosclerotic disease of lower extremities. The study was performed in the group of 28 (M/F 22/6) patients means aged 64.1 years with atherosclerotic diseases of lower extremities, in whom 2 weeks therapy with oxygen-ozone mixture was used. The control group consisted of 30 healthy volunteers in mean age 51.0 years. In the blood plasma obtained from the patients before and after treatment with oxygen-ozone mixture and from the control group determinations of t-PA and vWF antigen using ELISA were done. Both parameters were significantly increased in the patients before the treatment in comparison to the healthy controls. The treatment with oxygen-ozone therapy caused in patients slight statistically not significant raise of t-PA and vWF antigen showing the endothelial stimulation but not the destruction of vascular endothelium.


Asunto(s)
Arteriosclerosis/patología , Arteriosclerosis/terapia , Pierna/patología , Ozono/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Antígenos/sangre , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/fisiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oxígeno/farmacología , Oxígeno/uso terapéutico , Ozono/farmacología , Enfermedades Vasculares Periféricas/patología , Activador de Tejido Plasminógeno/sangre , Activador de Tejido Plasminógeno/efectos de los fármacos , Factor de von Willebrand
19.
Przegl Lek ; 54(1): 15-7, 1997.
Artículo en Polaco | MEDLINE | ID: mdl-9190627

RESUMEN

Protein C is the important regulating factor of coagulation and fibrinolytic system. It is known that surgery causes disturbances of haemostasis. The aim of work was to study the influence of different kind of surgery on the protein C activity. The study contained 102 operated patients in whom vascular operation (20), operation of prostate because of carcinoma (20) and hypertrophy (40), cholecystectomy (12) and operation of hernia (10) were performed. Protein C activity was measured using Kabi Diagnostika test applying chromogenic substrate. In the most of patients surgery caused on the 0 and 1st postoperative day the decrease of protein C activity and the return to the preoperative values in the next few days. The exception was the hernia operation which did not diminish protein C activity. It seems that the decrease of protein C after surgery was the effect of consumption of it in the extremely activated coagulation and fibrinolytic system during operation.


Asunto(s)
Proteína C/metabolismo , Procedimientos Quirúrgicos Operativos/efectos adversos , Anciano , Coagulación Sanguínea/fisiología , Colecistectomía/efectos adversos , Fibrinólisis/fisiología , Hernia/metabolismo , Herniorrafia , Humanos , Masculino , Persona de Mediana Edad , Enfermedades de la Próstata/metabolismo , Enfermedades de la Próstata/cirugía , Procedimientos Quirúrgicos Vasculares/efectos adversos
20.
Pneumonol Alergol Pol ; 66(3-4): 173-7, 1998.
Artículo en Polaco | MEDLINE | ID: mdl-9857661

RESUMEN

Twenty patients with recently recognised bronchial asthma and 22 age and sex-matched healthy control subjects were studied. In both groups the activated partial thromboplastin time (APTT), prothrombin ratio (INR), fibrinogen, euglobulin lysis time (ELT), platelet number and platelet adhesion and aggregation, tissue plasminogen activator antigen (t-PA Ag) and activity of plasminogen activator inhibitor (PAI-1) were tested and compared. Statistically significant differences between asthmatic and control groups concerning adhesion, aggregation, APTT and ELT were found. In asthmatic group after 14 days of prednisone administration in a dose of 20 mg/d statistically significant (p < 0.05) shortening of APTT, and a significant increase of adhesion, aggregation and PAI-1 activity were found. These results suggest that in asthmatic patients after prednisone treatment platelet activity appeared in a form of intensification of adhesion and of aggregation degree, also the activity of PAI-1 probably of the platelet origin increased.


Asunto(s)
Antiinflamatorios/farmacología , Asma/sangre , Asma/tratamiento farmacológico , Plaquetas/efectos de los fármacos , Inactivadores Plasminogénicos/metabolismo , Prednisona/farmacología , Adulto , Antiinflamatorios/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Tiempo de Tromboplastina Parcial , Agregación Plaquetaria/efectos de los fármacos , Recuento de Plaquetas/efectos de los fármacos , Prednisona/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA